A 3-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR [sustained release] in outpatients with mild to moderate Alzheimer's disease with donepezil as active control

Trial Profile

A 3-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR [sustained release] in outpatients with mild to moderate Alzheimer's disease with donepezil as active control

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Donepezil (Primary) ; Lecozotan (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Results presented in combination with results from the 203 study at the 2012 International Conference on Alzheimer's Disease.
    • 19 Jul 2012 Patient numbers changed from 229 to 372 as reported in the conference abstract
    • 03 Jul 2012 Eisai and Pfizer added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top